LONA — LeonaBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1620463 ·
Last close
$7.73
Market Cap
$72.83M
52W High
$11.12
52W Low
$6.72
ADV30
41,096
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -18,143,000 | -32,948,000 | 71,590,000 | 32,833,000 | 22,287,000 |
| Dec 2025 | 0 | — | -10,477,000 | -82,889,000 | 92,151,000 | 69,276,000 | 64,361,000 |
| Sep 2025 | 0 | — | -6,874,000 | -6,611,000 | 30,033,000 | 20,874,000 | 3,247,000 |
| Jun 2025 | 0 | — | -7,291,000 | -6,966,000 | 35,545,000 | 19,888,000 | 3,559,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,967,000
Investing CF
$-24,083,000
Financing CF
$82,471,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.55
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-544,703,000
Inventory
—
Receivables
$0
ST Investments
$34,846,000
EBIT TTM
$-42,785,000
Pretax Income TTM
$-129,414,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,178,000 | -105,609,000 | 92,151,000 | 64,361,000 | — | -45,729,000 |
| Dec 2024 | 0 | -96,775,000 | -96,940,000 | 58,779,000 | 13,938,000 | — | -97,170,000 |
| Dec 2023 | 0 | -126,937,000 | -117,672,000 | 160,245,000 | 30,057,000 | — | -100,753,000 |
| Dec 2022 | 0 | -88,855,000 | -95,639,000 | 258,153,000 | 23,016,000 | — | -72,469,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BSEM | BioStem Technologies, Inc. | $69.90M | $3.92 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $69.05M | $4.97 | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | $68.69M | $19.99 | — |
| CRDF | Cardiff Oncology, Inc. | $77.64M | $1.00 | — |
| ENZN | Viskase Holdings, Inc. | $67.50M | $4.71 | — |
News headlines (Yahoo Finance, 1h cache)
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
2026-08-17 12:26 · Yahoo
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 20:05 · Yahoo
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
2026-08-12 11:00 · Yahoo
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
2026-06-04 11:00 · Yahoo
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
2026-05-27 11:00 · Yahoo
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-07 20:05 · Yahoo
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
2026-05-07 13:20 · Yahoo
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
2026-04-23 20:05 · Yahoo
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
2026-04-21 11:00 · Yahoo
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
2026-03-26 21:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.